secwatch.observer — SEC 8-K summary
======================================

Issuer:     C4 Therapeutics, Inc. (CCCC)
CIK:        0001662579
Form:       8-K
Filed at:   2023-05-30T23:59:59+00:00
Accession:  0001628280-23-020025
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

C4 Therapeutics licenses CFT8919 to Betta Pharma for Greater China; receives $35M upfront/equity
--------------------------------------------------------------------------------

- $10M upfront cash + $25M equity investment from Betta affiliate at $4.49/share (10.2% ownership).
- Up to $357M in development/commercial milestones plus low-to-mid double-digit royalties on Greater China sales.
- C4T retains rights outside Greater China; eligible for low single-digit royalties on ex-China sales.
- CFT8919 is an oral BiDAC degrader targeting EGFR L858R NSCLC; IND submission to FDA expected H1 2023.
- Betta responsible for development/manufacturing/commercialization in licensed territories; C4T retains rest of world.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662579/000162828023020025/0001628280-23-020025-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662579/000162828023020025/cccc-20230529.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-020025

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer